Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
prognosis information were collected. Survival curves were plotted using the
Kaplan-Meier method and comparison with log-rank. Multivariate analysis
was estimated using the Cox proportional hazard model. Results: Totally, 92
patients were recruited including 57 of males and 35 females with median
age of 51 years old. Thirty-one patients were with thymoma and 61 with
thymic carcinoma. Thirty-six patients were with stage IVa and 56 with IVb.
The metastasis sites were as follows: plural/pericardial (n=35), lung (n=29),
lymph nodes (n=18), bone (n=16), liver (n=13),brain (n=3) and other sites (n=8)
. Among these, 20 were multi-sites metastasis . The median overall survival
for all patients was 25.4 months (95%CI:21.7-29.1). The median overall survival
was shorter in patients with than that without liver metastasis (15.9 vs.26.6
months,P=0.015). A same trend was found in patients with and without brain
metastasis (14.5vs.25.6 months,P=0,013) . In multivariate analyses, the brain
and liver metastasis were independent unfavorable prognostic factors ( P
were 0.015 and 0.008,respectively) . Conclusion: Our results suggest of TET
with different metastasis sites may have diverse prognosis. Liver and brain
metastasis were unfavorable factors for survival of TET patients.
Keywords: Liver Metastasis, Brain metastasis, Thymic epithelial tumors,
survival
POSTER SESSION 2 – P2.04: MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL
CANCER/OTHER THORACIC MALIGNANCIES
THYMIC MALIGNANCIES CLINICAL & TRANSLATIONAL –
TUESDAY, DECEMBER 6, 2016
P2.04-023 RARE FREQUENCY OF GENE VARIATION AND SURVIVAL
ANALYSIS IN THYMIC EPITHELIAL TUMORS
Zhengbo Song
Medical Oncology, Zhejiang Cancer Hospital, Hangzhou/China
Background: hymic epithelial tumor (TET) is a rare mediastinal neoplasm and
little is known about its genetic variability and prognostic factors. This study
investigated the genetic variability and prognostic factors of TET. Methods:
We sequenced 22 cancer-related hotspot genes in TET tissues and matched
normal tissues using Ion Torrent Ampliseq next-generation technology.
The panel was used to analyze 1800 mutational hotspots and targeted
regions in 22 genes: EGFR, KRAS, BRAF, PIK3CA, AKT1, ERBB2, PTEN, NRAS,
STK11,MAP2K1, ALK, DDR2, CTNNB1, MET, TP53, SMAD4, FBXW7,FGFR3,
NOTCH1, ERBB4, FGFR1 and FGFR2. Overall survival (OS) was evaluated
using Kaplan-Meier methods and compared with log-rank tests. Results: A
histological analysis of 52 patients with a median age of 52 years old showed
15 patients (28.8%) with thymic carcinoma, 5 with type A thymoma (9.6%), 8
with type AB (15.4%), 6 with type B1(11.5%), 9 with type B2 (17.3%)and 9 with
type B3 thymoma (17.3%). Pathologic stages at diagnosis included: 18 patients
with stage I, 11 patients with stage II, 13 patients with stage III, and 10 patients
with stage IV disease. Three gene mutations were identified, including two
with PIK3CA mutation, and one with EGFR mutation . The 3 patients with
mutant genes included two cases of thymoma (one with EGFR and the other
with PIK3CA mutation) in addition to a case of thymic carcinoma (PIK3CA
mutation). The 5-year survival rates were 77.7% in all patients. The 5-year
survival rates were 93.3%, 90.0%,76.9% and 22.9% corresponding to Masaoka
stages I, II, III, and IV (P < 0.001) . The 5-year survival rates were 100%, 100%,
83.3%, 88.9%, 65.6% and 60.9% in the histological subtypes of A, AB, B1, B2,
and B3 thymomas and thymic carcinoma, respectively (P = 0.012).No survival
difference was found between patients with and without gene mutation
(P=0.352). Conclusion: Hotspot gene mutations are rare in TET. PIK3CA and
EGFR mutations represent candidate driver genes and treatment targets in
TET. Masaoka stage and histological subtypes predict the survival of TET.
Keywords: next-generation sequencing, Prognosis, Thymic epithelial tumors,
Gene mutation
POSTER SESSION 2 – P2.04: MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL
CANCER/OTHER THORACIC MALIGNANCIES
THYMIC MALIGNANCIES CLINICAL & TRANSLATIONAL –
TUESDAY, DECEMBER 6, 2016
P2.04-024 THYMIC EPITHELIAL TUMORS AND RADIOTHERAPY
RESULTS
Sureyya Sarihan 1 , Ahmet Sami Bayram 2 , Cengiz Gebitekin 3 , Omer Yerci 4 , Deniz
Sigirli 5
1 Radiation Oncology, Uludag University, Faculty of Medicine, Bursa/Turkey,
2 Uludag University, Faculty of Medicine, Bursa/Turkey, 3 Thoracic Surgery, Uludag
University, Faculty of Medicine, Bursa/Turkey, 4 Pathology, Uludag University,
Faculty of Medicine, Bursa/Turkey, 5 Biostatistics, Uludag University, Faculty of
Medicine, Bursa/Turkey
Background: Thymic epithelial tumors (TET) treated with radiotherapy (RT)
was evaluated for treatment outcomes and prognostic factors on survival.
Methods: Between October 1995 and December 2013, 31 patients were
treated. The median age was 44 (range: 19-83). There were 25 thymoma, 4
thymic carcinoma (TC) and 2 thymic neuroendocrin carcinoma (NEC). The
incidence were found 13%, 39%, 39% and 9% for Masaoka stage I-II-III and IV,
and 3%, 16%, 61%, 13% and 6%, for WHO type A-AB-B-C and NEC, respectively.
Eighteen patients (58%) underwent R0 resection. Median RT dose was 5400
cGy (range: 1620-6596). Seven patients received a median of 6 cycles (range:
1-6) cisplatin-based adjuvant and 4 patients received weekly 60-70 mg/
m2 paclitaxel or 2-3 cycles standart chemotherapy concurrently. According
to prognostic risk stratification including Masaoka staging and WHO
classification, cases were divided to good (n: 10), moderate (n: 9) and poor (n:
12) risk groups. Survival was calculated from diagnosis.
Results: In January 2016, 22 cases lived with median 51.5 months (range:
2-170.5) follow-up. Recurrences were observed 9 (29%) of patients median
29.5 months (range: 6.5-105). Local control, mean overall (OS) and disease-free
survival (DFS) rates for all patients, were 86%, 119 months (range: 94-144)
and 116 months (range: 89-144), respectively. Local control were 100%, 89%
and 75% for good, moderate and poor risk groups, respectively (p=0.08).
There were a significant differences for Masaoka stage (I-II vs III-IV, p = 0.001,
p